Clinical Trial

Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism

Study acronym: STEM-PARK
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism. The study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.
Trial Details
NCT Number NCT07471230
Lead Sponsor Biocells Medical
Conditions Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere
Enrollment 120 participants
Start Date 2026-11-23
Primary Completion 2028-11-23 (estimated)
Study Completion 2029-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-13